Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 6/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787349 | 1.00 | CPN1 (0.44) | CPN1CPB2LCKPPARDZDHHC20 | |
| SCHEMBL793518 | 1.00 | CPN1 (0.44) | CPN1CPB2LCKPPARDZDHHC20 | |
| SCHEMBL772558 | 1.00 | CPN1 (0.44) | CPN1CPB2LCKPPARDZDHHC20 | |
| SCHEMBL1457468 | 0.90 | LCK (0.55) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL30801444 | 0.90 | LCK (0.55) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL28494198 | 0.90 | TSHR (0.46) | PPARDGPR84FFAR1 | |
| SCHEMBL1456490 | 0.90 | LCK (0.55) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL16046797 | 0.90 | LCK (0.55) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL31607401 | 0.90 | LCK (0.55) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL30023888 | 0.90 | LCK (0.55) | LCKPPARDZDHHC20ZDHHC2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8623897-B2 | Methods and compositions for treatment of diabetes and dyslipidemia | KAREUS THERAPEUTICS, SA (CH) | 2014-01-07 | — | — | US | disclosed |
| EP-2618824-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | Kareus Therapeutics SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040177-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071528-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | LIPC, PNLIP, LIPA | CPN1 3193/4885CPB2 1453/4885LCK 2920/4885 |
| US-20140121267-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | GPR119, FFAR1, INSR | CPN1 2157/4885CPB2 2854/4885LCK 1823/4885 |
| US-20140142178-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | DHCR7, INSR, GPR119 | CPN1 1599/4885CPB2 1572/4885LCK 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.